Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00661414 · ClinicalTrials.gov registry record · Phase 1

Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors

A Phase 1 study of Solid Tumors, sponsored by Lpath.

Completed
Registry status
Phase 1
Development phase
37
Enrollment target
3
Study locations

NCT00661414 is a Phase 1 study of Solid Tumors that has completed, run by Lpath. The registered enrollment target is 37 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00661414, a Phase 1 study of Solid Tumors, has completed, sponsored by Lpath.

COMPLETED
Registry status
Phase 1
Development phase
37 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to determine the safety, tolerability and highest dose of ASONEP that can safely be administered to patients with cancer who are no longer being helped by standard treatments.

Conditions Studied

Solid Tumors

Interventions

  • BIOLOGICAL ASONEP (sonepcizumab/LT1009)

Study Locations (3)

California

  • Pacific Oncology - San Diego
  • Premiere Oncology - Santa Monica

Arizona

  • Premiere Oncology - Scottsdale

Trial Details

FieldValue
Enrollment Target 37 participants
Start Date 2008-04
Est. Completion 2011-12
Phase Phase 1

Sponsor

Lpath

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00661414

The ClinicalTrials.gov registry entry for NCT00661414 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (87% lower). The listed sponsor is Lpath, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ASONEP (sonepcizumab/LT1009) is the first listed.

NCT00661414 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.

Frequently Asked Questions

What is clinical trial NCT00661414 about?

NCT00661414 is a clinical study titled "Safety Study of ASONEP (Sonepcizumab/LT1009) to Treat Advanced Solid Tumors". The purpose of this study is to determine the safety, tolerability and highest dose of ASONEP that can safely be administered to patients with cancer who are no longer being helped by standard treatments.

What is the current status of trial NCT00661414?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2008-04. Estimated completion is 2011-12.

What conditions does trial NCT00661414 study?

This clinical trial studies the following conditions: Solid Tumors.

What interventions are being tested in trial NCT00661414?

The interventions under investigation include: ASONEP (sonepcizumab/LT1009) (BIOLOGICAL).

Who is sponsoring clinical trial NCT00661414?

This trial is sponsored by Lpath, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00661414 being conducted?

This trial has 3 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Solid Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.